Results 11 to 20 of about 14,957,077 (381)

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma [PDF]

New England Journal of Medicine, 2017
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Stiff, J. Friedberg, I. Flinn, A. Goy, B. Hill, Mitchell R. Smith, A. Deol, U. Farooq, P. Mcsweeney, J. Muñoz, I. Avivi, J. Castro, J. Westin, J. Chavez, A. Ghobadi, K. Komanduri, R. Levy, E. Jacobsen, T. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, David D. Chang, J. Wiezorek, W. Go   +39 more
semanticscholar   +3 more sources

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

Nature, 2022
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system1.
R. Majzner, S. Ramakrishna, K. Yeom, Shabnum Patel, Harshini Chinnasamy, Liora M. Schultz, R. Richards, Li Jiang, Valentin V. Barsan, Rebecca Mancusi, Anna C. Geraghty, Zinaida Good, A. Mochizuki, Shawn M. Gillespie, A. Toland, Jasia Mahdi, Agnes Reschke, Esther H Nie, Isabelle Chau, M. Rotiroti, Christopher W. Mount, C. Baggott, Sharon A. Mavroukakis, Emily Egeler, J. Moon, C. Erickson, Sean Green, Michael Kunicki, M. Fujimoto, Zachary J Ehlinger, Warren D. Reynolds, Sreevidya Kurra, K. Warren, Snehit Prabhu, H. Vogel, L. Rasmussen, Timothy T. Cornell, S. Partap, Paul G. Fisher, C. Campen, M. Filbin, G. Grant, B. Sahaf, K. Davis, S. Feldman, C. Mackall, Michelle Monje   +46 more
semanticscholar   +1 more source

Counteracting CAR T cell dysfunction [PDF]

Oncogene, 2021
AbstractIn spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in vivo, conceivably induced by immunosuppressive tumor microenvironment (TME) and excessive antigen exposure.
Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, Stina L. Wickström, Angel Cid-Arregui, Rolf Kiessling   +5 more
openaire   +2 more sources

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E., DeBerg, Hannah A., Enstrom, Mark R., Gersuk, Vivian, Gottardo, Raphaël, Hanafi, Laïla-Aïcha, Hawkins, Reed, Kiem, Hans-Peter, Linsley, Peter S., Maloney, David G., Pande, Dnyanada, Riddell, Stanley R., Sheih, Alyssa, Turtle, Cameron J., Voillet, Valentin, Wohlfahrt, Martin E., Yajima, Masanao   +16 more
core   +1 more source

Improving CAR T-Cell Persistence [PDF]

International Journal of Molecular Sciences, 2021
Over the last decade remarkable progress has been made in enhancing the efficacy of CAR T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in hematological settings, patients that respond to CAR T therapies remain at risk of relapsing due to several factors including poor T-cell expansion and lack of long ...
Violena Pietrobon, Lauren Anne Todd, Anghsumala Goswami, Ofir Stefanson, Zhifen Yang, Francesco Marincola   +5 more
openaire   +2 more sources

Engineering CAR-T cells [PDF]

Biomarker Research, 2017
Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients' or donors' blood.
Cheng Zhang, Jun Liu, Jiang F. Zhong, Xi Zhang   +3 more
openaire   +3 more sources

Approved CAR T cell therapies [PDF]

, 2018
Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute ...
Kros, J.M. (Johan), Li, J. (Jin), Zheng, P.P. (Pingpin)   +2 more
core   +15 more sources

CAR T cells produced in vivo to treat cardiac injury

Science, 2022
Description Making CAR T cells in vivo Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al. designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the ...
Joel G. Rurik, I. Tombácz, A. Yadegari, Pedro O. Méndez Fernández, Swapnil V. Shewale, Li Li, T. Kimura, O. Soliman, Tyler E. Papp, Yin-king Tam, B. Mui, S. Albelda, E. Puré, C. June, H. Aghajanian, D. Weissman, H. Parhiz, J. Epstein   +17 more
semanticscholar   +1 more source

Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological cancers and is currently being investigated for solid tumours, including high-grade glioma brain tumours.
Abler, Daniel, Adhikarla, Vikram, Barish, Michael, Branciamore, Sergio, Brown, Christine E, Cho, Heyrim, Frankhouser, David, Gutova, Margarita, Machuca, Vanessa, Maestrini, Davide, Rockne, Russell C, Sahoo, Prativa, Wang, Dongrui, Yang, Xin   +13 more
core   +2 more sources

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

New England Journal of Medicine, 2020
BACKGROUND Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR)
Michael L. Wang, J. Muñoz, A. Goy, F. Locke, C. Jacobson, B. Hill, J. Timmerman, H. Holmes, S. Jaglowski, I. Flinn, P. Mcsweeney, D. Miklos, J. Pagel, M. Kersten, N. Milpied, H. Fung, M. Topp, R. Houot, A. Beitinjaneh, W. Peng, Lianqing Zheng, J. Rossi, R. Jain, A. Rao, P. Reagan   +24 more
semanticscholar   +1 more source